BH3 mimetic antagonists to BCL-2 and MCL-1 has been considered as an anti-tumor strategy to induce cell death in acute myeloid leukemia (AML), and resistance to BH3 mimetics has been identified as a critical clinical problem (Bhatt et al., 2020). This evidence concerns the gene MCL1 and acute myeloid leukemia.